
Cytokinetics, Incorporated: shareholders and insiders
Price
$51.32
November 18, 2026Market cap $6.3B
What Ploutos Investor adds for Cytokinetics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$53M
11 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan90%
- The rest10%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $45M by 10 people
- 2025: no buys, sold $8.1M by 7 people
- 2026: no buys, sold $45M by 10 people
- Nov 17, 2026Fady Ibraham MalikEVP Research & DevelopmentKind10b5-1
- Nov 17, 2026Fady Ibraham MalikEVP Research & DevelopmentKind10b5-1
- Nov 17, 2026Fady Ibraham MalikEVP Research & DevelopmentKind10b5-1
- Nov 17, 2026Jeffrey HessekielChief Legal & Admin OfficerKind
- Nov 16, 2026Robert I BlumPresident & CEOKind10b5-1
- Nov 16, 2026Robert I BlumPresident & CEOKind10b5-1
- Nov 16, 2026Robert I BlumPresident & CEOKind10b5-1
- Nov 16, 2026Robert I BlumPresident & CEOKind10b5-1
- Nov 9, 2026B Lynne ParshallDirectorKind10b5-1
- Nov 9, 2026B Lynne ParshallDirectorKind10b5-1
- Nov 3, 2026Fady Ibraham MalikEVP Research & DevelopmentKind10b5-1
- Nov 3, 2026Fady Ibraham MalikEVP Research & DevelopmentKind10b5-1
- Nov 2, 2026Robert I BlumPresident & CEOKind10b5-1
- Nov 2, 2026Robert I BlumPresident & CEOKind10b5-1
- Oct 20, 2026Fady Ibraham MalikEVP Research & DevelopmentKind10b5-1
- Oct 20, 2026Fady Ibraham MalikEVP Research & DevelopmentKind10b5-1
- Oct 16, 2026Nancy WysenskiDirectorKind
- Oct 16, 2026Edward M. MD KayeDirectorKind
- Oct 16, 2026Robert Arthur HarringtonDirectorKind
- Oct 16, 2026James M DalyDirectorKind
- Oct 16, 2026Wendell WierengaDirectorKind
- Oct 16, 2026John T HendersonDirectorKind
- Oct 12, 2026Robert I BlumPresident & CEOKind10b5-1
- Oct 12, 2026Robert I BlumPresident & CEOKind10b5-1
- Oct 6, 2026Fady Ibraham MalikEVP Research & DevelopmentKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Fady Ibraham MalikEVP Research & Development | 10b5-1 | 3,500 | $7.80 | $27.3K | Form 4 |
| Nov 17, 2026 | Fady Ibraham MalikEVP Research & Development | 10b5-1 | 3,300 | $51.73 | $170.7K | Form 4 |
| Nov 17, 2026 | Fady Ibraham MalikEVP Research & Development | 10b5-1 | 200 | $52.59 | $10.5K | Form 4 |
| Nov 17, 2026 | Jeffrey HessekielChief Legal & Admin Officer | 15.1K | $52.62 | $794.9K | Form 4 | |
| Nov 16, 2026 | Robert I BlumPresident & CEO | 10b5-1 | 7,500 | $10.60 | $79.5K | Form 4 |
| Nov 16, 2026 | Robert I BlumPresident & CEO | 10b5-1 | 5,077 | $53.22 | $270.2K | Form 4 |
| Nov 16, 2026 | Robert I BlumPresident & CEO | 10b5-1 | 2,223 | $54.08 | $120.2K | Form 4 |
| Nov 16, 2026 | Robert I BlumPresident & CEO | 10b5-1 | 200 | $55.21 | $11.0K | Form 4 |
| Nov 9, 2026 | B Lynne ParshallDirector | 10b5-1 | 2,445 | $54.17 | $132.4K | Form 4 |
| Nov 9, 2026 | B Lynne ParshallDirector | 10b5-1 | 2,555 | $55.26 | $141.2K | Form 4 |
| Nov 3, 2026 | Fady Ibraham MalikEVP Research & Development | 10b5-1 | 3,500 | $7.80 | $27.3K | Form 4 |
| Nov 3, 2026 | Fady Ibraham MalikEVP Research & Development | 10b5-1 | 3,500 | $62.93 | $220.3K | Form 4 |
| Nov 2, 2026 | Robert I BlumPresident & CEO | 10b5-1 | 7,500 | $10.60 | $79.5K | Form 4 |
| Nov 2, 2026 | Robert I BlumPresident & CEO | 10b5-1 | 7,500 | $62.81 | $471.1K | Form 4 |
| Oct 20, 2026 | Fady Ibraham MalikEVP Research & Development | 10b5-1 | 3,500 | $7.80 | $27.3K | Form 4 |
| Oct 20, 2026 | Fady Ibraham MalikEVP Research & Development | 10b5-1 | 3,500 | $64.01 | $224.0K | Form 4 |
| Oct 16, 2026 | Nancy WysenskiDirector | 97 | $63.92 | $6.2K | Form 4 | |
| Oct 16, 2026 | Edward M. MD KayeDirector | 195 | $63.92 | $12.5K | Form 4 | |
| Oct 16, 2026 | Robert Arthur HarringtonDirector | 195 | $63.92 | $12.5K | Form 4 | |
| Oct 16, 2026 | James M DalyDirector | 195 | $63.92 | $12.5K | Form 4 | |
| Oct 16, 2026 | Wendell WierengaDirector | 97 | $63.92 | $6.2K | Form 4 | |
| Oct 16, 2026 | John T HendersonDirector | 352 | $63.92 | $22.5K | Form 4 | |
| Oct 12, 2026 | Robert I BlumPresident & CEO | 10b5-1 | 7,500 | $10.60 | $79.5K | Form 4 |
| Oct 12, 2026 | Robert I BlumPresident & CEO | 10b5-1 | 7,500 | $62.88 | $471.6K | Form 4 |
| Oct 6, 2026 | Fady Ibraham MalikEVP Research & Development | 10b5-1 | 3,500 | $7.80 | $27.3K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 27, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by CYTK's officers and directors from 2006 up to November 18, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- T. Rowe Price Investment Management, Inc.Share of class14.5%
- Vanguard Capital ManagementShare of class5.21%
- State StreetShare of class5.10%
- Wellington Management Group LLPwith 2 more personsShare of class5.10%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 14.5% | 17.72M | Feb 17, 20264 filings since May 7, 2025 | 13G/A | |
| Vanguard Capital Management | 5.21% | 6.42M | Apr 29, 2026 | 13G | |
| State Street | 5.10% | 7.14M | Nov 10, 20262 filings since Nov 10, 2025 | 13G | |
| Wellington Management Group LLPwith 2 more persons | 5.10% | 7.12M | Aug 13, 2026 | 13G/A |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter-68%
- Millennium Mgmt (Englander)In the quarter+153%
- D.E. ShawIn the quarter-75%
- AQR CapitalIn the quarter+69%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | – | – | 0.21% | |
| Citadel Advisors (Griffin) | 204.2K | -68% | $14M | 0.01% |
| Millennium Mgmt (Englander) | 277.1K | +153% | $18M | 0.01% |
| D.E. Shaw | 266.5K | -75% | $18M | 0.01% |
| AQR Capital | 274.4K | +69% | $18M | 0.01% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 15.1% of its shares outstanding were held short, -3.6% since the report before.
- Shares held short
- 18.63M
- 15.1%
- Since the report before19.33M on Sep 30, 2026
- -3.6%
- 8.7
- 2.14M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 87%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 14.13M
- Nov 15, 2023: Shares held short 13.69M
- Nov 30, 2023: Shares held short 13.45M
- Dec 15, 2023: Shares held short 14.66M
- Dec 29, 2023: Shares held short 15.08M
- Jan 12, 2024: Shares held short 13.75M
- Jan 31, 2024: Shares held short 13.58M
- Feb 15, 2024: Shares held short 13.83M
- Feb 29, 2024: Shares held short 14.53M
- Mar 15, 2024: Shares held short 14.80M
- Mar 28, 2024: Shares held short 13.23M
- Apr 15, 2024: Shares held short 14.04M
- Apr 30, 2024: Shares held short 13.67M
- May 15, 2024: Shares held short 14.19M
- May 31, 2024: Shares held short 16.42M
- Jun 14, 2024: Shares held short 16.04M
- Jun 28, 2024: Shares held short 17.38M
- Jul 15, 2024: Shares held short 17.46M
- Jul 31, 2024: Shares held short 17.83M
- Aug 15, 2024: Shares held short 18.63M
- Aug 30, 2024: Shares held short 18.21M
- Sep 13, 2024: Shares held short 17.84M
- Sep 30, 2024: Shares held short 17.32M
- Oct 15, 2024: Shares held short 15.54M
- Oct 31, 2024: Shares held short 15.69M
- Nov 15, 2024: Shares held short 14.59M
- Nov 29, 2024: Shares held short 14.03M
- Dec 13, 2024: Shares held short 13.73M
- Dec 31, 2024: Shares held short 13.71M
- Jan 15, 2025: Shares held short 14.03M
- Jan 31, 2025: Shares held short 13.65M
- Feb 14, 2025: Shares held short 15.07M
- Feb 28, 2025: Shares held short 14.07M
- Mar 14, 2025: Shares held short 14.22M
- Mar 31, 2025: Shares held short 14.33M
- Apr 15, 2025: Shares held short 13.95M
- Apr 30, 2025: Shares held short 14.48M
- May 15, 2025: Shares held short 15.60M
- May 30, 2025: Shares held short 14.50M
- Jun 13, 2025: Shares held short 14.01M
- Jun 30, 2025: Shares held short 15.02M
- Jul 15, 2025: Shares held short 15.93M
- Jul 31, 2025: Shares held short 15.52M
- Aug 15, 2025: Shares held short 15.33M
- Aug 29, 2025: Shares held short 13.83M
- Sep 15, 2025: Shares held short 14.26M
- Sep 30, 2025: Shares held short 14.11M
- Oct 15, 2025: Shares held short 14.20M
- Oct 31, 2025: Shares held short 13.79M
- Nov 14, 2025: Shares held short 14.38M
- Nov 28, 2025: Shares held short 12.95M
- Dec 15, 2025: Shares held short 13.34M
- Dec 31, 2025: Shares held short 13.84M
- Jan 15, 2026: Shares held short 13.39M
- Jan 30, 2026: Shares held short 13.31M
- Feb 13, 2026: Shares held short 14.78M
- Feb 27, 2026: Shares held short 15.37M
- Mar 13, 2026: Shares held short 15.66M
- Mar 31, 2026: Shares held short 15.85M
- Apr 15, 2026: Shares held short 14.89M
- Apr 30, 2026: Shares held short 15.90M
- May 15, 2026: Shares held short 16.46M
- May 29, 2026: Shares held short 15.50M
- Jun 15, 2026: Shares held short 14.77M
- Jun 30, 2026: Shares held short 17.57M
- Jul 15, 2026: Shares held short 17.05M
- Jul 31, 2026: Shares held short 15.30M
- Aug 14, 2026: Shares held short 16.32M
- Aug 31, 2026: Shares held short 17.44M
- Sep 15, 2026: Shares held short 17.48M
- Sep 30, 2026: Shares held short 19.33M
- Oct 15, 2026: Shares held short 18.63M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading53.6% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 53.6% of the shares in the reported trades were short sales, against 61.8% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 53.6%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 61.8%
- Change
- -8.2 pts
- Short sales a dayon average, of 996.5K shares
- 534.0K
- More than atof 3,656 US-listed companies, same days
- 61%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 66.9%
- Oct 13, 2026: Short sales 62.7%
- Oct 14, 2026: Short sales 64.1%
- Oct 15, 2026: Short sales 65.6%
- Oct 16, 2026: Short sales 70.1%
- Oct 19, 2026: Short sales 77.2%
- Oct 20, 2026: Short sales 73.7%
- Oct 21, 2026: Short sales 64.2%
- Oct 22, 2026: Short sales 55.1%
- Oct 23, 2026: Short sales 48.4%
- Oct 26, 2026: Short sales 56.4%
- Oct 27, 2026: Short sales 55.3%
- Oct 28, 2026: Short sales 53.5%
- Oct 29, 2026: Short sales 49.9%
- Oct 30, 2026: Short sales 64%
- Nov 2, 2026: Short sales 67.4%
- Nov 3, 2026: Short sales 57.4%
- Nov 4, 2026: Short sales 70.9%
- Nov 5, 2026: Short sales 55.5%
- Nov 6, 2026: Short sales 47.1%
- Nov 9, 2026: Short sales 24.4%
- Nov 10, 2026: Short sales 46.1%
- Nov 11, 2026: Short sales 60.3%
- Nov 12, 2026: Short sales 42.3%
- Nov 13, 2026: Short sales 56.4%
- Nov 16, 2026: Short sales 40.8%
- Nov 17, 2026: Short sales 70.7%
- Nov 18, 2026: Short sales 52.6%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Robert I BlumPresident & CEODirectly282.7K
- Fady Ibraham MalikEVP Research & DevelopmentDirectly153.9K
- Jeffrey HessekielChief Legal & Admin OfficerDirectly92.8K
- John T HendersonDirectorDirectly78.8K
- Sung LeeEVP, Chief Financial OfficerDirectly63.2K
- Andrew CallosEVP, Chief Commercial OfficerDirectly58.6K
- Wendell WierengaDirectorDirectly35.7K
- Nancy WysenskiDirectorDirectly34.1K
- Muna BhanjiDirectorDirectly26.4K
- Wendall WierengaDirectorDirectly24.8K
- Robert Arthur HarringtonDirectorDirectly22.1K
- Robert WongVP, Chief Accounting OfficerDirectly16.7K
- Edward M. MD KayeDirectorDirectly10.6K
- Robert E LandryDirectorDirectly8,184
- B Lynne ParshallDirectorDirectly5,784
- James M DalyDirectorDirectly3,585
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Robert I BlumPresident & CEO | 282.7K | – | Nov 16, 2026 | Form 4 |
| Fady Ibraham MalikEVP Research & Development | 153.9K | – | Nov 17, 2026 | Form 4 |
| Jeffrey HessekielChief Legal & Admin Officer | 92.8K | – | Nov 17, 2026 | Form 4 |
| John T HendersonDirector | 78.8K | – | Oct 16, 2026 | Form 4 |
| Sung LeeEVP, Chief Financial Officer | 63.2K | – | Jul 1, 2026 | Form 4 |
| Andrew CallosEVP, Chief Commercial Officer | 58.6K | – | Aug 31, 2026 | Form 4 |
| Wendell WierengaDirector | 35.7K | – | Oct 16, 2026 | Form 4 |
| Nancy WysenskiDirector | 34.1K | – | Oct 16, 2026 | Form 4 |
| Muna BhanjiDirector | 26.4K | – | May 27, 2026 | Form 4 |
| Wendall WierengaDirector | 24.8K | – | Apr 21, 2025 | Form 4 |
| Robert Arthur HarringtonDirector | 22.1K | – | Oct 16, 2026 | Form 4 |
| Robert WongVP, Chief Accounting Officer | 16.7K | – | Jun 3, 2024 | Form 4 |
| Edward M. MD KayeDirector | 10.6K | – | Oct 16, 2026 | Form 4 |
| Robert E LandryDirector | 8,184 | – | Sep 15, 2026 | Form 4 |
| B Lynne ParshallDirector | 5,784 | – | Nov 9, 2026 | Form 4 |
| James M DalyDirector | 3,585 | – | Oct 16, 2026 | Form 4 |
A lower bound: it counts only the 16 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- TCAFT. Rowe Price Capital Appreciation Equity ETFWeight in the fund1.34%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.18%
- IBBiShares Biotechnology ETFWeight in the fund0.79%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.79%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.65%
- IWMiShares Russell 2000 ETFWeight in the fund0.35%
- IJKiShares S&P Mid-Cap 400 Growth ETFWeight in the fund0.33%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.33%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.32%
- IJHiShares Core S&P Mid-Cap ETFWeight in the fund0.32%
29 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 383
- Q4 2025: Managers 432
- Q1 2026: Managers 443
- Q2 2026: Managers 482
Institutional investors by quarter
The fund managers holding CYTK, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 482 managers held 160M shares, worth $13.7B. During the quarter 94 opened a position, 55 closed one, 230 added and 102 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+21%
- T. Rowe Price Investment ManagementIn the quarter+6.8%
- Wellington Management GroupIn the quarter-13%
- Vanguard Portfolio ManagementIn the quarter+15%
- State StreetIn the quarter+13%
- Vanguard Capital ManagementIn the quarter+11%
- FMRIn the quarter-53%
- Avoro Capital AdvisorsIn the quarter+50%
- Bank of AmericaIn the quarter+48%
- Geode Capital ManagementIn the quarter+15%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 20.09M | +21% | $1.7B |
| T. Rowe Price Investment Management | 18.72M | +6.8% | $1.6B |
| Wellington Management Group | 6.93M | -13% | $591M |
| Vanguard Portfolio Management | 6.71M | +15% | $572M |
| State Street | 6.49M | +13% | $553M |
| Vanguard Capital Management | 6.12M | +11% | $521M |
| FMR | 5.03M | -53% | $429M |
| Avoro Capital Advisors | 5.00M | +50% | $426M |
| Bank of America | 4.64M | +48% | $395M |
| Geode Capital Management | 3.71M | +15% | $316M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Cytokinetics's filings show?
Who buys and sells is one part of Cytokinetics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have CYTK's insiders bought or sold?
From May 27, 2026 to Nov 18, 2026 Cytokinetics's insiders bought 0 and sold $26M of shares on the market. 97% of the sales were under set 10b5-1 plans.
Which well-known managers hold CYTK?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $18M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.